Immatics, N.V., a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, reported that Bristol Myers Squibb has exercised its option and entered into an exclusive worldwide license for the first T cell receptor engineered T cell therapy (TCR-T) candidate from their ongoing collaboration. Under the terms of the 2019 multi-target strategic collaboration agreement, which was expanded in 2022, Immatics is developing and valid...